AI-based drug discovery company Recursion raises $121M at a $646M valuation; VCs invested about $1B in AI drug discovery startups in 2018, up from $237M in 2016 (Robert Langreth/Bloomberg)

Robert Langreth / Bloomberg:
AI-based drug discovery company Recursion raises $121M at a $646M valuation; VCs invested about $1B in AI drug discovery startups in 2018, up from $237M in 2016  —  Alphabet's DeepMind cracked a problem that long vexed biologists, heating up a technological arms race in health care